18-Methoxycoronaridine: a putative anti-addictive agent


  • Dhasanai Suriyachan Pharmacology and Toxicology Unit, Department of Medical Sciences, Faculty of Science, Rangsit University, Patumthani 12000, Thailand


ibogaine, 18-methoxycoronaridine, anti-addiction


18-Methoxycoronaridine (18-MC) is a synthetic analog of ibogaine, an indole alkaloid found in the roots of Tabernanthe iboga. It has been reported that ibogaine possesses multiple effects, especially in treating drug addiction, but it can induce whole-body tremor, Purkinje cell loss in the cerebellum, bradycardia, and flaccid paralysis in rats.  On the contrary, 18-MC produces none of the above-mentioned toxic effects. At a single dose (40 mg/kg, i.p.) 18-MC reduced self-administration of nicotine, morphine, cocaine, ethanol, and methamphetamine without any apparent toxicity in addicted rats.  The mechanism of anti-addictive action of 18-MC is believed to mediate via blocking the alpha3beta4 nicotinic receptors in the habenulo-interpeduncular pathway modulating the dopaminergic mesolimbic pathway known to be involved in drug addiction. From a close observation on the information about 18-MC, it has been found that this compound is not available for clinical use at present because of its clinical trial in progress to be approved by the USFDA.  Once 18-MC has been approved, it will be a useful drug for the treatment of polydrug abuse.


Alper, K. R. (2001). Ibogaine: A review. The Alkaloids: Chem. Biol, 56, 1-38.

Alper, K.R., Lotsof, H. S., & Kaplan, C. D. (2008). The ibogaine medical subculture. J. Ethnopharmacol, 115, 9-24.

Ball, J. C., & Ross, A. (1991). The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome. New York, USA: Springer-Verlag.

Berger, P., Gawin, F., & Kosten, T. R. (1989). Treatment of cocaine abuse with mazindol. Lancet, 1, 283.

Buie, J. (1994). 46 new drugs for mental illness could reach market within 3 to 6 years. Psychiatric Times, XI, 44.

Carnicella, S., He, D. Y.,Yowell, Q. V., Glick, S. D., & Ron, D. (2010). Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administation. Addict. Biol, 15, 424-433.

Colchin, J., & Mushlin, B. E. (1976). Effect of agonist-antagonist interaction on the development of tolerance and dependence. Ann. N.Y.Acad. Sci, 281, 224-251.

Delander, G. E., Portoghese, P. S., & Takemori, A. E. (1984). Role of spinal mu opioid receptors in the development of morphine tolerance and dependence. J. Pharmacol. Exp. Ther, 231, 91-96.

Evans-Schultes, R., & Hofmann, A. (1980). Tabernanthe Iboga. The botany and chemistry of hallucinogens (pp. 235-239). Illinois, USA: Charles C. Thomas Publisher.

Forsyth, A. J., Farquhar, D., Gemmell, M., Shewan, D., & Davies, J. E. (1993). The dual use of opioids and temazepam by drug injectors in Glasgow (Scotland). Drug Alcohol Depend, 32, 277-280.

Frischer, M. (1992). Estimated prevalence of injecting drug use in Glasgow. Br. J. Addict, 87, 235-243.

Ghitza, U.E., Zhai, H., Wu, P., Airavaara, M., Shaham, Y., & Lu, L. (2010). Role of BDNF and GDNF in drug reward and relapse : a review. Neurosci. Biobehav. Rev, 35, 157-171.

Glick, S. D., Kuehne, M. E., Maisonneuve, I. M., Bandarage, U. K., & Molinari, H. H. (1996). 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Res, 719, 29-35.

Glick, S. D., Maisonneuve, I. M., Visker, K. E., Fritz, K. A., Bandarage, U. K., & Kuehne, M. E. (1998). 18-Methoxycoronaridine attenuates nicotine-induced dopamine release and nicotine preferences in rats. Psychopharmacology, 139, 274-280.

Glick, S. D., Maisonneuve, I. M., Hough, L. B., Kuehne, M. E., & Bandarage, U. K. (1999). () 18-Methoxycoronaridine : A novel iboga alkaloid congener having anti-addictive efficacy. CNS Drug Reviews, 5, 27-42.

Glick, S. D., & Maisonneuve, I. M. (2000). Development of novel medications of drug addiction. The legacy of an African shrub. Ann. N.Y. Acad. Sci, 909, 88-103.

Glick, S. D., Maisonneuve, I. M., & Dickinson, H. A. (2000). 18-MC reduces amphetamine and nicotine self-administration in rats. Neuroreport, 11, 2013-2015.

Glick, S. D., Maisonneuve, I. M., & Szumlinski, K. K. (2001). Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. The Alkaloids: Chem. Biol, 56, 39-53.

Glick, S. D., Maisonneuve, I. M., & Kitchen, B. A. (2002). Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha3beta4 nicotinic receptors. Eur. J. Pharmacol, 448, 185-191.

Glick, S. D., Sell, E. M., & Maisonneuve, I. M. (2008). Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration. Eur. J. Pharmacol, 599, 91-95.

Glick, S. D., Sell, E. M., McCallum, S. E., & Maisonneuve, I. M. (2011). Brain areas mediating 34 nicotinic antagonist effects of 18-MC on nicotine self-administration. Eur. J. Pharmacol, 669,


Green-Sadan, T., Kinor, N., Roth-Deri, I., Geffen-Aricha, R., Schindler, C.J., & Yadid, G. (2003). Transplantation of glial cell line-derived neurotrophic factor-expressing cells into the striatum and nucleus accumbens attenuates acquisition of cocaine self-administration in rats. Eur. J. Neurosci, 18, 2093-2098.

He, D. Y., McGough, N. H., Ravindranathan, A., Jeanblanc, J., Logrip, M. L., Phamluong, K., Janak, P. H., & Ron, D. (2005). Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J. Neurosci, 25, 619-628.

He, D. Y., & Ron, D. (2006). Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting action of the antiaddiction drug, Ibogaine. FASEB J, 20, 2420-2422.

Hecht, S. S. (1999). Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst, 91, 1194-1210.

Heckel, J. (2011). Editor’s Note. Central Illinois Business Magazine, January.

Hough, L. B., Pearl, S.M., & Glick, S. D. (1996). Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration. Life Sci, 58, 119-122.

Klaassen, C. D. (2001). Casarett & Doull’s toxicology. 6th ed. New York, USA: McGraw-Hill.

Lüscher, C. (2007). Drugs of abuse. Basic and clinical pharmacology (pp. 511-525). 10th ed. Singapore: McGraw-Hill.

Maisonneuve, I. M., & Glick, S. D. (1999). Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine. Eur. J. Pharmacol, 383, 15-21.

Maisonneuve, I. M., & Glick, S. D. (2003). Anti-addictive actions of an iboga alkaloid congener : a novel mechanism for a novel treatment. Pharmacol. Biochem. Behav, 75, 607-618.

Mash, D. C., Staley, J. K., Baumann, M. H., Rothman, R. B., & Hearn, W. L. (1995). Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci, 57, PL 45-50.

Mash, D. C., Kovera, C. A., Buck, B. E., Norenberg, M. D., Shapshak, P., Hearn, W. L., & Sanchez-Ramos, J. (1998). Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann.N.Y.Acad. Sci, 844, 274-292.

Mash, D. C., Kovera, C. A., Pablo, J.,Tyndale, R., Ervin, F. R., Kamlet, J. D., & Hearn,

W. L. (2001). Ibogaine in the treatment of heroin withdrawal. The Alkaloids : Chem. Biol, 56, 155-171.

Meltzer, H. Y. (1987). Psychopharmacology : The third generation of progress. New York, USA: Raven Press.

O’Brien, C. P. (2001). Drug addiction and drug abuse. Goodman & Gilman’s the pharmacological basis of therapeutics (pp. 621-642). 10th ed. New York, USA: McGraw-Hill.

O’Hearn, E., & Molliver, M.E. (1993). Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience, 55, 303-310.

Panchal, V., Taraschenko, O. D., Maisonneuve,

I. M., & Glick, S. D. (2005). Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine. Eur. J. Pharmacol, 525, 98-104.

Preston, K. L., Sullivan, J. T., Berger, P., & Bigelow, G. E. (1993). Effects of cocaine abuse and in combination with mazindol in human cocaine abusers. J. Pharmacol. Exp. Ther, 267, 296-307.

Resnick, R. B., Schuyten-Resnick, E., & Washton, A. M. (1980). Assessment of narcotic antagonists in the treatment of opioid dependence. Annu. Rev. Pharmacol. Toxicol, 20, 463-474.

Rezvani, A. H., Overstreet, D. H., Yang,Y., Maisonneuve, I. M., Bandarage, U. K., Kuehne, M. E., & Glick, S. D. (1997). Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacol. Biochem. Behav, 58, 615-619.

Ron, D., & Janak, P. H. (2005). GDNF and addiction. Rev. Neurosci, 16, 277-285.

Singbartl, G., Zetler, G., & Schlosser, L. (1973). Structure-activity relationships of intracerebrally injected tremorigenic indole alkaloids. Neuropharmacology, 12, 239-244.

Szumlinski, K. K., Maisonneuve, I. M., & Glick, S. D. (2000). The potential anti-addictive agent, 18-methoxycoronaridine, blocks the sensitized locomotor and dopamine responses produced by repeated morphine treatment. Brain Res, 864, 13-23.

Szumlinski, K. K., McCafferty, C. A., Maisonneuve, I. M., & Glick, S. D. (2000). Interaction between 18- methoxy- coronaridine (18-MC) and cocaine: dissociation of behavioural and neuro- chemical sensitization. Brain Res, 871, 245-258.

Taraschenko, O. D., Shulan, J. M., Maisonneuve, I. M., & Glick, S. D. (2007). 18-MC acts in the medial habenula and interpedun- cular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens. Synapse, 61, 547-560.

Torrens, M., San, L., & Cami, J. (1993). Buprenorphine versus heroin dependence: comparison of toxicologic and psychopa- thologic characteristics. Am. J. Psychiatry, 150, 822-824.

World Health Organization. (2011). 10 Facts on the tobacco epidemic and its control. Retrieved April 18, 2012, from http://www.who.int/features/factfiles/tobacco_epidemic/en/index.html

Zhang, W., Ramamoorthy, Y., Tyndale, R. F., Glick, S. D., Maisonneuve, I. M., Kuehne, M. E., & Sellers, E. M. (2002). Metabo- lism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronari- dine by genetically variable CYP2C19. Drug Metab. Dispos, 30, 663-669.




How to Cite

Suriyachan, D. . (2023). 18-Methoxycoronaridine: a putative anti-addictive agent. Journal of Current Science and Technology, 2(2), 175–181. Retrieved from https://ph04.tci-thaijo.org/index.php/JCST/article/view/590



Review Article